Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more
Genmab AS (GMAB) - Net Assets
Latest net assets as of December 2025: $37.18 Billion USD
Based on the latest financial reports, Genmab AS (GMAB) has net assets worth $37.18 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($81.86 Billion) and total liabilities ($44.68 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $37.18 Billion |
| % of Total Assets | 45.42% |
| Annual Growth Rate | 15.33% |
| 5-Year Change | 67.51% |
| 10-Year Change | 670.31% |
| Growth Volatility | 53.31 |
Genmab AS - Net Assets Trend (2002–2025)
This chart illustrates how Genmab AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genmab AS (2002–2025)
The table below shows the annual net assets of Genmab AS from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $37.18 Billion | +1.32% |
| 2024-12-31 | $36.70 Billion | +16.09% |
| 2023-12-31 | $31.61 Billion | +15.86% |
| 2022-12-31 | $27.28 Billion | +22.91% |
| 2021-12-31 | $22.20 Billion | +16.08% |
| 2020-12-31 | $19.12 Billion | +36.11% |
| 2019-12-31 | $14.05 Billion | +75.29% |
| 2018-12-31 | $8.01 Billion | +27.78% |
| 2017-12-31 | $6.27 Billion | +29.95% |
| 2016-12-31 | $4.83 Billion | +38.43% |
| 2015-12-31 | $3.49 Billion | +71.51% |
| 2014-12-31 | $2.03 Billion | +208.24% |
| 2013-12-31 | $659.52 Million | +72.12% |
| 2012-12-31 | $383.19 Million | -21.22% |
| 2011-12-31 | $486.42 Million | -54.96% |
| 2010-12-31 | $1.08 Billion | -16.74% |
| 2009-12-31 | $1.30 Billion | -40.73% |
| 2008-12-31 | $2.19 Billion | -24.09% |
| 2007-12-31 | $2.88 Billion | +79.36% |
| 2006-12-31 | $1.61 Billion | +43.69% |
| 2005-12-31 | $1.12 Billion | -5.27% |
| 2004-12-31 | $1.18 Billion | +8.70% |
| 2003-12-31 | $1.09 Billion | -22.35% |
| 2002-12-31 | $1.40 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genmab AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2676123602100.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $26.06 Billion | 70.09% |
| Common Stock | $63.59 Million | 0.17% |
| Other Comprehensive Income | $-1.15 Billion | -3.10% |
| Other Components | $12.21 Billion | 32.84% |
| Total Equity | $37.18 Billion | 100.00% |
Genmab AS Competitors by Market Cap
The table below lists competitors of Genmab AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bavarian Nordic A/S
PINK:BVNKF
|
$1.62 Billion |
|
FRESHWORKS CL.A DL-00001
F:7DF
|
$1.62 Billion |
|
Vericel Corp Ord
NASDAQ:VCEL
|
$1.62 Billion |
|
Pylon Technologies Co. Ltd. A
SHG:688063
|
$1.62 Billion |
|
KEIHAN HOLDINGS CO. LTD.
F:59X
|
$1.62 Billion |
|
Companhia de Saneamento de Minas Gerais
SA:CSMG3
|
$1.62 Billion |
|
The Chemours Company
MX:CC
|
$1.62 Billion |
|
Schneider National Inc
NYSE:SNDR
|
$1.62 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genmab AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 36,697,000,000 to 37,180,752,000, a change of 483,752,000 (1.3%).
- Net income of 6,142,507,928 contributed positively to equity growth.
- Share repurchases of 2,742,760,550 reduced equity.
- New share issuances of 5,500,000,000 increased equity.
- Other comprehensive income decreased equity by 1,640,969,061.
- Other factors decreased equity by 6,775,026,317.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $6.14 Billion | +16.52% |
| Share Repurchases | $2.74 Billion | -7.38% |
| Share Issuances | $5.50 Billion | +14.79% |
| Other Comprehensive Income | $-1.64 Billion | -4.41% |
| Other Changes | $-6.78 Billion | -18.22% |
| Total Change | $- | 1.32% |
Book Value vs Market Value Analysis
This analysis compares Genmab AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.45x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.24x to 0.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $6.26 | $26.56 | x |
| 2003-12-31 | $4.76 | $26.56 | x |
| 2004-12-31 | $4.46 | $26.56 | x |
| 2005-12-31 | $3.58 | $26.56 | x |
| 2006-12-31 | $4.13 | $26.56 | x |
| 2007-12-31 | $6.56 | $26.56 | x |
| 2008-12-31 | $4.90 | $26.56 | x |
| 2009-12-31 | $2.89 | $26.56 | x |
| 2010-12-31 | $2.41 | $26.56 | x |
| 2011-12-31 | $1.08 | $26.56 | x |
| 2012-12-31 | $0.83 | $26.56 | x |
| 2013-12-31 | $1.27 | $26.56 | x |
| 2014-12-31 | $3.55 | $26.56 | x |
| 2015-12-31 | $5.74 | $26.56 | x |
| 2016-12-31 | $7.81 | $26.56 | x |
| 2017-12-31 | $10.10 | $26.56 | x |
| 2018-12-31 | $12.92 | $26.56 | x |
| 2019-12-31 | $22.08 | $26.56 | x |
| 2020-12-31 | $29.02 | $26.56 | x |
| 2021-12-31 | $33.61 | $26.56 | x |
| 2022-12-31 | $41.33 | $26.56 | x |
| 2023-12-31 | $47.96 | $26.56 | x |
| 2024-12-31 | $56.78 | $26.56 | x |
| 2025-12-31 | $59.31 | $26.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genmab AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.52%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.89%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 2.20x
- Recent ROE (16.52%) is above the historical average (-14.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -34.26% | 0.00% | 0.00x | 1.13x | $-619.25 Million |
| 2003 | -30.11% | -478.75% | 0.06x | 1.09x | $-435.76 Million |
| 2004 | -35.16% | -10124.65% | 0.00x | 1.08x | $-533.31 Million |
| 2005 | -35.18% | -399.56% | 0.07x | 1.22x | $-505.47 Million |
| 2006 | -27.26% | -323.31% | 0.08x | 1.12x | $-598.99 Million |
| 2007 | -13.30% | -72.40% | 0.13x | 1.37x | $-671.70 Million |
| 2008 | -44.10% | -129.52% | 0.23x | 1.49x | $-1.18 Billion |
| 2009 | -77.92% | -172.46% | 0.26x | 1.71x | $-1.14 Billion |
| 2010 | -29.76% | -55.23% | 0.23x | 2.30x | $-429.46 Million |
| 2011 | -122.60% | -169.94% | 0.22x | 3.22x | $-645.01 Million |
| 2012 | -127.12% | -100.51% | 0.29x | 4.42x | $-525.44 Million |
| 2013 | 17.04% | 16.93% | 0.38x | 2.63x | $46.41 Million |
| 2014 | 14.82% | 35.43% | 0.30x | 1.41x | $98.00 Million |
| 2015 | 21.90% | 67.39% | 0.29x | 1.12x | $414.84 Million |
| 2016 | 24.59% | 65.36% | 0.35x | 1.09x | $704.41 Million |
| 2017 | 17.59% | 46.65% | 0.36x | 1.05x | $476.33 Million |
| 2018 | 18.37% | 48.66% | 0.36x | 1.06x | $670.71 Million |
| 2019 | 15.42% | 40.37% | 0.35x | 1.08x | $761.20 Million |
| 2020 | 24.88% | 47.06% | 0.48x | 1.11x | $2.85 Billion |
| 2021 | 13.32% | 35.13% | 0.34x | 1.11x | $737.40 Million |
| 2022 | 19.98% | 37.59% | 0.48x | 1.10x | $2.72 Billion |
| 2023 | 13.77% | 26.42% | 0.47x | 1.12x | $1.19 Billion |
| 2024 | 21.38% | 36.44% | 0.47x | 1.25x | $4.17 Billion |
| 2025 | 16.52% | 25.89% | 0.29x | 2.20x | $2.42 Billion |
Industry Comparison
This section compares Genmab AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genmab AS (GMAB) | $37.18 Billion | -34.26% | 1.20x | $1.62 Billion |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |